The Patent Finder

Terms ending in 2041

Biodesix, Inc.

Every in-force patent on Biodesix, Inc.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,476,003Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings
In force
 · High confidence
Biodesix, Inc.In forceHigh confidence
US 11,894,147Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings
In force
 · High confidence
Biodesix, Inc.In forceHigh confidence
US 12,094,587Apparatus and Method for Identification of Primary Immune Resistance in Cancer Patients
In force
 · High confidence
Biodesix, Inc.In forceHigh confidence
US 11,542,340Antibodies Targeting Pulmonary Nodule Specific Biomarkers and Uses Thereof
In force
 · High confidence
Biodesix, Inc.In forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited